I'm about to show you five stocks that could define your portfolio for the next months and going into 2026. And here's the thing: November is not just another month. We're sitting literally at a pivotal moment where AI is meeting healthcare, where energy companies are printing cash like there's no tomorrow, where scientific breakthroughs are happening faster than most people realize. So the stakes? Missing this window could mean watching from the sidelines while others capitalize on some of the most powerful trends in the market. By the end of this video, you will know exactly what I'm looking at and why these five companies could be massive winners. Now, let's get into it. I'm Felix Prime. I'm an ex-investment banker. I've seen how the system works from the inside, yet, none of the following is financial advice. I'm not telling you to buy companies. My goal is to show you the process, show you the data points I look at to find what I think might be gems. But you've got to come to your own conclusion. Otherwise, you're going to get left really behind because you're going to be acting out of FOMO, and that's the worst thing you can do. That's also why I founded the GOAT Academy, where we've taught literally over 20,000 students how to invest like the pros. And that's also why I co-founded TradeVision.io to give you regular investors like you and me the tools, the data that we need to actually compete. So my mission here is simple. I want to teach you how to think like an institutional investor, but trade and invest like a smart individual. Because when you understand what's really driving the market, you stop gambling and you start investing. So today I'm going to walk you through five stocks across five completely different sectors. I'm not just telling you what to buy, I'm teaching you how to think about these opportunities so you can make intelligence decisions yourself. So please make your own decisions. Don't rely on me. Now, the stocks are not going to hold you hostage straight away. They are here. A XOM TXG D-N-U-T and Zyme. This is a tool that I have inside of our community. You can get access to that. There's a link down below, Felix Frenzellog slash resource. And we're going to look at the data, we're going to look at the charts, we're going to look at what's driving these. So the first stock is literally called A. So since that's a ticker symbol, it stands for Agilent Technologies. They're the invisible giant that's powering modern medicine. Now, most of you have never heard of this, but it's absolutely crucial. Life science tools. Think about this for a second. Every single drug you've ever taken, every vaccine, every cancer treatment being developed right now, they all depend on super sophisticated equipment and tools. The companies making these drugs can't do their job without the machines that help them discover it and test it and manufacture them. And here is what's actually really exciting. This industry is about to go into hyperdrive. We're talking about a market growing at over 7% a year. Some forecasts showing the US market alone hitting over$270 billion by 2034. And that's driven by three forces. First, personalized medicine. It's becoming real. Instead of giving everyone the same drug and hoping it works, doctors are now tailoring treatments to your specific DNA. And that requires incredibly advanced analytical tools. Second, pharma companies are spending money like crazy on research. Their revenues have gone up 60% in the last five years, and every dollar they spend means more demand for the tools they need to do their research. And then third, and this is huge, AI is supercharging the pace of discovery. AI doesn't just help analyze data faster, it's completely changing how we understand biology. And guess what? You can't run AI on biological data without the right instruments. So the industry itself is a rocket ship. So let me show you the company that's dominating this space. And it is Agilent Technologies. Now let me look showing the data points for these first. I always look at these key data points here. Let me zoom in a bit a bit now. There we go. So a gross margin of 52%. I know it says fail. The gold standard is 60, but that's typically more for like a service business. This is actually a very good set of numbers. The return on invested capital is very, very good. Generally speaking, I look at that number and I think, well, if I want that kind of return, they should be creating that kind of return. They generate pretty good free cash flow, not gold standard yet, but pretty good. They've got plenty of money to pay their debt. And it's trading at 34 times P. You know, your hyperscalers are trading at 45 right now, right? So what do these guys actually do? Well, they make essential instruments, software, and consumables that laboratories around the world absolutely cannot live without. Think of them as the picks and the shovels of the biotech gold rush. So everyone's focused on which drug company might find the next blockbuster. I'm a big fan of biotech stocks right now, but there are like thousands, and finding the right one is a bit like the needle in the haystack, so why not buy the shovel? So Agilin is literally selling the equipment to all of these biotech stocks. And if you look at the stock chart, it's trading around that sort of$145 right now. But if you zoom out a little bit, you see kind of an interesting pattern, right? It's been going up and down quite a bit. It was trading at about 180 in 2021 when the demand for all the stuff is way, way, way, way lower. So why do I like it here? Well, for us, this isn't the first time I've flagged this in in our community. You know, we're looking at this a little earlier because there were definitely a bottoming out here, and then there was the conservative entry point, it was probably there. I can't remember exactly where we called it. We then zigzagged a little bit here. That was your second entry point there. That was number two, this is number one. Um, you might be thinking, how the heck do I learn this? Like we got some videos out on this, but honestly, if you actually want to learn this in a serious way, I think you need someone to look over your shoulder. I think you need somebody to guide you. I think you need somebody watch your portfolio and see what you're doing and spot your mistakes and your errors and see where you need refinement so you become a better investor, a safer investor. And the only way I think that really happens is if you find yourself a mentor. Now, we're doing something bonkers this week, which is my guys convinced me that Black Friday is real, which I know for you Americans seems odd, but it's just not a thing outside the US, as far as I'm aware. I've certainly never seen it. Um, so they convinced me we should actually do a crazy offer, which is what we're actually doing this week. So if you want to partake of that crazy offer, then you can book a free strategy call. Literally write direct, which again is something we never really do. Um you can go to feedixfriends.org slash freedom. It's a free strategy call with my team. It's about 45 minutes long or so. And we can really chew through like where do you want to get to? This is something that would help you. You can ask us all the questions you ever wanted to ask us. And if you then decide to join us, you're gonna get a crazy deal, which you'll never get. Like we never discount. I always believe in we should just over-deliver as insanely as humanly possible, and that's what we do, which is why I never really want to go the other direction. But we're doing it because apparently Black Friday is a big thing in the US. So there you go. Um, you won. So check it out. The link's down below. But what am I seeing right now? We we're seeing this little pattern up here, right? So let me zoom in a little bit for you about, and then I'll explain a little bit more what this company really does, and so on. But what we want to look at is what were the highs, what were the closing highs? So there was one here, and then we're basically slightly below that. So to me, if this thing moves up just to exactly that sort of line here, which sits at about 148, excuse me, I'm running with a mouse, that to me would be the entry. Because then we've exceeded another zone here, and we're doing that quite nicely. The trend is looking up. So to me, that would be then the next entry point after the previous ones. So as I say, here was one, um, here was one, right? So that was one, and that was one here, number two. To me, this would be number three if and only if we break out of that. And if we look a little bit at their latest data, it was actually very, very good. I don't know why I'm saying data now. Obviously, I'm thinking about Black Friday too much. You're getting to me with your accents. 1.7 billion revenue. Earnings beat expectations. Now, earnings, what is that? What are earnings? Earnings is a really fancy word for profits, right? That's really all I really care about. So profits above expectations is a beautiful thing. And then you look at most of the biotech companies, but they haven't got any profits. They're just promising to you that they might cure something somewhere down the road. And these guys are also guiding for even better revenue growth. For 2026, they're projecting 6.8 billion in revenue. Just let that sink in. 6.8 billion revenue. So this is not some biotech startup in their mom's garage, right? They're accelerating their growth. The whole industry is going through a recovery, a re-renaissance, essentially. And and their secret weapon, it's recurring revenue. 60% there's my percent button, 60% of sales come from consumables. And that's the holy grail. Um, there's actually a similar stock, in a sense, in the pet sector. It's called IDEX, IDXX. Similar story. They make a lot of money through consumables. So once a lab buys one of your instruments, which costs hundreds of thousands of dollars, they need to keep buying supplies and maintenance from Agilin year after year. It's like selling somebody a printer and then getting paid every time they need ink cartridges, which is pretty much the printing model, which is why printers are virtually free, but the ink is like gold, right? So they've got about a 20% market share in their core segments. They're going head-to-head with other giants like Thermo Fisher and Danaher and so on. But Agilin has carved out a niche with deep expertise in areas like mass spectrometry, which is basically a superpowered way of identifying chemicals and proteins and so on. And analysts, they're starting to like it. Now, analysts are like sheep, I didn't give them that much credit, to be honest, but as biopharma spending is growing, interest rates come down, farmer spending tends to go up, Agilent should grow too. So it's not flashy, but it's indispensable. So there is stock numero uno. Now, reminder if you're serious about investing and you're looking to learn from my mentors of retired investment bankers, there's literally never been a better time. We never discount. But we're doing this crazy Black Friday deal. So take action. Book a free call for yourself, FelixSpencer.org slash freedom. It is the one and the one chance only in a year to get take advantage of that. Now, the second stock is a cash flow monster. And energy stocks are back in fashion. Okay, and now you're thinking, Felix, oil really isn't this old news? Listen, the energy sector has completely transformed itself. And most people haven't noticed it. This is not your grandfather's oil company anymore. Here's what's changed. For years, oil companies were obsessed with pumping more and more oil, even when it destroyed shareholder value. They'd spent billions drilling wells that barely made money, and all in the name of growth, right? But something shifted. Industry got disciplined. They realized investors wanted profits, not promises. So now these companies are focused on three things efficiency, profitability, and returning money to shareholders. And it's actually working. US production, oil production has hit record levels. We're taking, um, we're talking rather 13 million barrels per day roughly this year. And once again, AI is making exploration and digital optimization better. Their costs keep going down, oil prices are stable. So it gives these guys plenty of room to make money. And even better, they're using all that cash to buy back their own shares and pay massive dividends. So the wave of mergers and acquisitions is creating a super efficient giant here. And that brings us to the king of all the giants, which, in my humble opinion, is XOM, Xon Mobile. Now you might look at these numbers and you go, that gross margin is a fail. ROIC is below 10%, it's not amazing. Free cash flow is below 10%, not amazing. Okay, plenty of money. They have basically no debt or they can pay it easily. But then look at that. It's trading at 15 times PE. So it's a cheap company with very decent numbers that are improving and huge buybacks and dividends. And they are the largest energy company in America. And they're printing money, right? So it's trading right now, it's trading right now at about 117. And for those of you guys who've followed me for a little while, you always hear me talk about a heartbeat pattern. Now, you've ever seen one that's textbook. Well, this is pretty much it. And the longer these phases go on for, the more violent, typically the eventual upside. Now, I say eventual because we're not quite there yet. We're almost there. We're literally on Friday, we closed at exactly the same level we were at at the recent high here. That means we're very close. We also gapped up, which is another huge positive. And the momentum, that yellow line there, is suddenly going from flat to actually moving upwards. So we're at the cusp, I believe, of a breakout. Doesn't mean you should run out and buy it. I'm just saying that's what I'm seeing here. And I don't think people have really paid attention yet. But our indicators here are starting to really, really improve here on Friday, bigly improvement. So I'm quite liking it from where I'm sitting. And are they making money? Well, let me give you one or two numbers. So last quarter, one quarter only, they made 7.5 billion, not revenue, but profits. Just one quarter. They beat earnings expectations, and they generated almost 15 billion in operating cash flow in just three months. What do they do with that cash? Well, they returned 9.4 billion to shareholders, if I could spell shareholders, through dividends and buybacks in a single quarter. That's a typo, right? So their secret is two world-class assets. First, they have a in Guyana, if you haven't been following this, Exxon discovered massive oil reserves of the coast of Guyana, uh, most profitable find in recent history. That oil basically jumps out of the ground when you talk to it sweetly. Um, so very, very low cost. And then they have the Permian Basin into Texas. So they acquired pioneer natural resources. So Exxon basically now dominates the most productive oil field in America. Combine these two assets together, and well, you've got basically unstoppable growth. Now, Exxon doesn't stop there. They don't just drill the oil, they also refine it, they market it, they make chemicals from it, and that integration acts as kind of a hedge. So when oil prices go up, their upstream business makes a killing. When oil prices drop, their refining business can benefit from cheaper inputs. They kind of win either way. It's also one of Warren Buffett's latest buys, which um may or may not mean something, but you know, some endorsement there. Now, stock number three. Now we're gonna get a little bit more crazy. Uh, we're looking at again, all the data is you can get access to this better stocks GPT in our community. There's a link down below for the expensive logs resource. And it is ticker symbol TGX, 10X genomics. Now, you might have never heard of them, you might have never heard of what they do, which is single cell biology. It's about to explode, I'm told, and we're moving into something very, very kind of exciting and cutting edge. So imagine you're trying to understand what's wrong with a patient who has, say, cancer, right? Traditional tests look at big chunks of tissue and give you an average reading, but there's a problem with that. Not all cells are the same. One cancer cell might be completely different from the one right next to it. So, what if you could analyze each individual cell? What if you could see exactly which cells are cancerous, which ones are fighting back, and which ones are just along for the ride? Well, that's single-cell genomics. And this technology is revolutionizing biology, and the market is growing insanely rapidly at about 15% a year. And there's some forecasts out there with really, really wild protections. But why is it such a big deal? Because precision medicine is different. Something like cancer isn't one disease, it's thousands of diseases that all look very similar. But if you understand a tumor at the single cell level, researchers can then identify new drug targets, develop treatments that are personalized to each patient. And that's already happening with oncology, and it's just the beginning. So, secondly, here, the technology unlocks secrets about diseases we barely understand, think Alzheimer's, autoimmune diseases, complex neurology conditions, all that kind of stuff. This gives us an insight where literally we see things that were impossible before. And then third, the technology gets better and better and cheaper. AI is helping scientists analyze all these data silos that we didn't have before, and it's becoming accessible. You have big initials, you have like the Zuckerberg billion cell project is pouring money into this field and so on. So it's one of these rare moments where you're watching a technology go from interesting to indispensable. Now, 10x Genomics is a pioneer. By the way, I I never promote a company because they tell me to do something. We never take any money from anybody. I get offered it every single day, and we say, nope, I take zero sponsorship on the on the uh for anything. I don't need to, so I won't. So it's just me doing research. Again, doesn't mean you should run out and buy it, but maybe it's something worth looking into. These guys are the market leader. Um, they're kind of leading this charge, and they've built the platform that's become the gold standard in academic labs and pharma companies. So their instruments, their consumables, their software make it possible to do research that was literally fiction just a decade ago. Now, if you look at their stock chart, what do you see? Remember the last stock we looked at, and I was talking about a heartbeat pattern, heart skips a beat kind of thing. That's exactly what we're seeing here, right? And what are you then seeing? Well, you had this sort of slight downtrend, and then here you have a bigly breakout, a breakout above the recent high there. So that looks pretty interesting. Your volume not spiking up, you have our indicator sort of peaking up. So this is kind of an interesting moment for the stock. Now, I want to be clear, this is a very volatile stock, right? This thing was trading at almost an all-time high up there somewhere, 200 and something percent. So, you know, they say buy and hold, right? Well, you'd be down 91% if you bought and hold this one. So I'm not a huge fan of that. If you want to buy and hold, buy the index. You can buy and hold that one. Individual stocks, it's a dangerous thing to do. Now, last quarter, they beat the expectations. Yeah, they're losing money. I want to be very clear on that. They're losing about 22 cents a share right now. So, like most of these biotech kind companies, you know, they're doing that. But they are on a path towards profitability. And that's why they really what matters. A bit like the first company we talked about, their consumables' revenue is growing year over year. And that tells you that the labs aren't just buying the instruments, they're actually using them heavily, which means recurring revenue. We expect about 150, 160 million in revenue for the next quarter. And there's another thing I like about these guys, which is a problem for most companies in the sector, they have about 482 million in cash. So they have plenty of runway to keep innovating without needing to raise money. They also have an estimated 40 to 50 percent market share in single-cell analysis. And that's basically dominant. So they've built the system and everybody's using what they're doing, who's in this space. Now, Wall Street is a little behind on this one. Most of the analysts out there that I looked up say hold, gets a couple of moderate buys, price targets around$15,$19. Skepticism, why? Because they're not profitable yet. And Wallsy doesn't really understand non-profitable businesses because they can't model them, you see. They like to put a spreadsheet together with profits and then multiply it by some number and come out with an easy valuation. You can't do that if something isn't yet profitable. Now, this is uh this is a risky thing, absolutely. This is more risky than the other stocks we talked about, and probably more risky than the next one we're talking about, except the next stock is more dangerous for your arteries than it is for your portfolio, I'd say. Um, the next stock is not something you probably hear me talk about very often. Quick service restaurants. They still work. And donuts are apparently addictive and delicious, some people are saying. So this whole industry, fast food, fast casual food, it is just insanely resilient. 330 billion sales this year, despite all the headwinds like labor costs and food inflation, this industry keeps adapting and thriving. So, so why crispy cream? Look at the numbers here. It's a fail on everything, right? Well, I don't know how you can have a negative PE ratio, interesting, but especially free. Um, margin isn't great. Um fundamentals are just weak, weak, weak, weak, weak, weak, but they are a comeback kit. It's an iconic American brand, right? It's the original glazed donut, you know, all that stuff. It's sort of a nostalgia brand. Some people say it's delicious. I can't stand a donut, to be honest with you. Um actually, it's not true. I like those old ones with the with the jam in the middle, you know, those kind of classic ones. Those ones are quite hard to resist. Um, but if you look at the stock chart here, this thing is an absolute value destroyer, right? It's literally come down about 80%, by and hold, they say. Um get yourself a mentor and and learn how to not have to do go through the the the these drawdowns. Literally, it's entirely avoidable that you're down 70% on something. It's entirely avoidable. You can learn that very, very quickly. So, what do we see here? Well, you see this sort of you know, heartbeat thing going on here, but trending up ever so slightly. Um, the lows are getting a little higher each time. So you get a little bit of an uptick there. And even if you just look at that yellow line there, which is the 50-day moving average line, right? Bottomed out here, and it's picking up steam a little bit. We've just crossed the purple line here, which is the 150-day moving average line, at which point companies tend to become investable. So that was here, right? We retested that here, so we were kind of onto a good path there. So for me, the timing seems quite good. Earnings were very good, nice beat, profitable for the quarter. And we are literally right now where we are, above all the recent closing prices, like just a smidgen above it. And I'm showing you this because turnarounds can be incredibly lucrative if you catch them at approximately the right time. And if you look at their last quarter's data, you can see turnaround, turnaround all over it. Why? Because, well, revenue was down, but that was intentional. They closed unprofitable stores, and organic revenue actually grew, which means the core business is stabilized. But what matters most is profitability is improving. They actually made money. They made$40 million. Doesn't sound like a lot, and it isn't, but it means profit margins expanded. They beat earnings expectations and they generate a positive free cash flow of 50 million. Doesn't sound too exciting, but that's literally the turnaround moments. They're starting to generate cash. Things are getting interesting. What's their strategy? Well, they're using a hub and spoke model. So instead of building all these expensive stores everywhere, they produce donuts in central kitchens and then they deliver fresh donuts daily to thousands of locations in grocery stores and in gas stations. So they're partnered with Walmart, Kroger, and major other retailers. And it's a capital light and it's highly scalable as a strategy. So you can walk into a Walmart in Texas or on a 7-Eleven in Florida and you can grab yourself a fresh Krispy Kreme donut, which will clock up your arteries. That was not possible a few years ago. They have about 10% of the US donut market, which puts them third, by the way, behind Duncan and a couple of regional players. But they have the most powerful brand recognition in the whole sector. Wall Street? Wall Street says hold, hold, careful, careful children. And that's again because they don't really get turnaround stories. But if I look at the recent earnings, it says to me management is executing. The profit margin is expanding. We're seeing cash flow. So I'm starting to see what I like to see. It's early, it's a little risky for sure, like there's risk with everything, but I'm seeing this is a stock that's bottoming out and it could give us some really, really potential nice returns if it plays out the way I hope it will. Again, not telling you to buy it. You're going to come to your own conclusion, but there is that. Now, least but not last, we've got a completely different. It's a moonshot stock, and I sort of threw it in as a bonus. It is a biotech company called Zymeworks, ticker symbol Z Y-M-E. These make something called anti-body. Let me write it out for you because this is not, this is not intuitive in any way, shape, or form. This is called anti-body drug conjugates. Conjugates reminds me of Latin lessons. Um there is an abbreviation for this, thankfully. It's called ADCs. Um what does it mean? Okay. The chemotherapy kind of works, but it's brutal, right? Kills the cancer cells, but it typically also kills the patient. Well, the healthy cells, causes terrible side effects. So what if you could deliver the chemo directly and only to the cancer cells? That's ADC. So think of it like a small smart bomb versus carpet bombing. So traditional chemical chemotherapy is literally carpet bombing. It hits everything. But AECs are your smart bombs. They find the cancer cells, they attach to them, and then they release their payload right there. This technology is literally exploding, hence the bomb analogy, and it's projected to grow at between 15 to 30% a year, depending on who you listen to, maybe even faster. So it's one of the highest growth rates in all of healthcare. Why the massive growth? Well, first, cancer rates even keep growing globally, which is high style and food and exposure to chemicals and everything else, at least in my humble opinion. So these ADCs are providing better treatments, more effective, and the science is advancing very rapidly. So you've got new innovations in how these drugs are designed, making them even more precise and more powerful. So the next generation ADCs are coming. And third, we've got Big Pharma. They're going all in. Pfizer just spent 43 billion to buy C gen, which is an ADC pioneer. That tells you everything about how seriously the industry is taking this. So there are over 400 ADC candidates in development worldwide. So this is not speculative, it's literally the future of oncology. And Zymeworks, well, they're one of the key indicators. It's a clinical stage biotech company. They're developing next generation ADCs and other cancer treatments. And clinical stage means they don't have products on the market yet. We've only been very clear about that. They're not generating revenue yet. They're in the RD phase, makes them higher risk, but also higher potential and higher reward. Stock at$16, as I open it up for you. Not Zion, not there we go. And uh we zoom out a bit. Well, yeah, again, like most of these stocks got killed by higher interest rates. So again, if you bought this in 2021, well, you'd still be down about 70%, right? So don't buy and hold things forever, please, especially not in really cyclical industries like us. Um so why are these stocks so volatile? Trial results, partnerships, um, interest rates, and so on. But the last quarter, their revenue jumped to 27 million. Nice surprise on profits. The net loss narrowed, they're managing their expenses better, and they again have almost 300 million in cash. So it gives them some runway well into late 2027 to survive without having to raise any money. So it means they're not gonna have to dilute you anytime soon. Analysts, for some strange reason, actually really like this one. There is this sort of buy-bye-buy some for most of the analysts out there. So the coverage and the momentum on this thing is quite good, even though it's still down 70% from its real its its 2021 highs. So that's essentially my thesis on this. I'm seeing a uh rather large heartbeat pattern here, which is actually trending up. So is it possible it's gonna pull back a little bit? Yeah, um, I prefer it if it pulls out back out of that zone. I think that'd be the easier entry point. But you could also take the contrarian position that maybe if it bounces off down here, that would be the sweet spot. That's obviously for you to judge whether you want to buy this at all. But we've got a bunch of catalysts coming for this. They've submitted INDs for new drugs. Um, that's coming in mid-2026, I think. They have a phase three data for one of their um their cancer treatments that's coming out this quarter. So positive results in any of these could unlock a lot of money, right? A lot of money, a lot of future royalties. The partnership model means they can get funding and validation from big pharma investors. Uh, but the risk is still massive. It's a clinical stage biotech company. I'm not gonna lie to you, this is massively risky. Um, but if you want to understand this better, you want to understand more about risk management, which is really what making money is all about, then find yourself someone you can learn from. Because to me, I see this and I see opportunity. Others will see this and they see lots of risk. And it's really a question of just like how you would handle an investment like this. And the only thing that got me to where I'm today is my lovely mentors who are tremendous people and will work for the big investor banks. And you can have a chat with us, see if that might be the right step for you to get control of your risk and your management and your finances and get. towards your goals. You can do that for free at foodexfriends.org slash freedom. Have a chat with us. And if you got some value out of this, share with somebody else and they might get some value out of it too.